Advertisement

Pharmacy World & Science

, Volume 31, Issue 4, pp 473–480 | Cite as

The development of a sleep disorder screening program in Australian community pharmacies

  • Adam Tran
  • Joanne M. Fuller
  • Keith K. Wong
  • Ines Krass
  • Ron Grunstein
  • Bandana SainiEmail author
Research Article

Abstract

Objective To develop, pilot and determine the feasibility of a sleep-specific screening and awareness program in community pharmacies. Setting The screening was piloted in five Australian community pharmacies. Method The Pharmacy Tool for Assessment of Sleep Health was constructed by drawing on known relationships between sleep disorders, and lifestyle factors, medical conditions and medications. Four validated instruments were used in the screening tool: the Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), Multivariable Apnea Prediction Index (MAPI) and International Restless Legs Syndrome Study Group Screening Criteria (IRLS). These instruments were used to predict the participant’s risk of a sleep disorder and the results were compared with reported lifestyle, medical and medication factors. On-site training of consenting pharmacists was provided, followed by an eight week client recruiting and screening period. Feedback was elicited from participating pharmacists and clients. Main outcome measure The feasibility of, and trends found from, the developed screening tool and protocol. Results Of 167 clients who requested or were invited to participate by pharmacists, 84 (50.3%) were screened. Analysis of collected data indicated that 33.3%, 21.4% and 27.4% of participants were at risk of having or developing insomnia, obstructive sleep apnea (OSA) and restless legs syndrome (RLS) respectively, while 38.1% were not at risk of any of the screened disorders. OSA odds increased 12.8 times (95% CI: 3.2–50.4) with diabetes and 4.9 times (1.2–20.9) with opioid use, while shift workers were 8.4 times (1.6–43.2) more likely to have insomnia. Participants and pharmacists reported the screening protocol and instrument was user friendly and feasible. Conclusion The development and pilot of this screening tool was successful. The prevalence of sleep disorders in the sampled population was high but generally consistent with previous studies on the general population. Furthermore, associations found may form a foundation for a clinical algorithm to identify those at a higher risk of having or developing a sleep disorder. Further work is required to validate this screening tool in the community pharmacy context.

Keywords

Community pharmacy Screening Sleep disorders Sleep health 

Abbreviations

ESS

Epworth Sleepiness Scale

ISI

Insomnia Severity Index

MAPI

Multivariable Apnea Prediction Index

IRLS

International Restless Legs Syndrome Study Group Screening Criteria

OSA

Obstructive sleep apnea

RLS

Restless legs syndrome

EDS

Excessive daytime sleepiness

QoL

Quality of life

PSG

Polysomnography

BMI

Body mass index

Notes

Acknowledgements

We would like to thank all participants and pharmacists involved in the study.

Funding

This study was funded under the Fourth Community Pharmacy Agreement Research & Development Program (Investigator Initiated Grant, Identification number: Q0052R1931), The Pharmacy Guild of Australia.

Conflict of interest statement

There was no conflict of interest influencing the publication of this pilot study.

References

  1. 1.
    Anonymous. Wake up Australia: the value of healthy sleep: access economics; 2004. http://www.accesseconomics.com.au/publicationsreports. Accessed 4 Aug 2008.
  2. 2.
    Colagiuri S, Colagiuri R, Conway B, Grainger D, Davey P. DiabCo$t Australia: Assessing the burden of Type 2 Diabetes in Australia. 2003. Diabetes Australia; Canberra. ISBN 1 875690 20 4.Google Scholar
  3. 3.
    Britt H, Miller GC, Charles J, Bayram C, Pan Y, Henderson J et al. General practice activity in Australia 2006–07, in General Practice Series. 2008, Australian Institute of Health and Welfare: Canberra. http://www.aihw.gov.au/ Accessed 4 August 2008.
  4. 4.
    Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411–8. doi: 10.1016/0006-3223(95)00188-3.CrossRefPubMedGoogle Scholar
  5. 5.
    Engleman HM, Douglas NJ. Sleep 4: sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004;59:618–22. doi: 10.1136/thx.2003.015867.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    McNicholas WT, Bonsigore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29:156–78. doi: 10.1183/09031936.00027406.CrossRefPubMedGoogle Scholar
  7. 7.
    Peppard PE, Young T, Palta M, Skatrud J. Prospective study on the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378–84. doi: 10.1056/NEJM200005113421901.CrossRefPubMedGoogle Scholar
  8. 8.
    Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–46. doi: 10.1016/j.sleep.2004.03.006.CrossRefPubMedGoogle Scholar
  9. 9.
    Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med. 2006;7:545–52. doi: 10.1016/j.sleep.2006.01.004.CrossRefPubMedGoogle Scholar
  10. 10.
    Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology. 2008;70:35–42. doi: 10.1212/01.wnl.0000287072.93277.c9.CrossRefPubMedGoogle Scholar
  11. 11.
    Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20:705–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Marshall NS, Wilsmore BR, McEvoy RD, Wheatley JR, Dodd MJ, Grunstein RR. Polysomnography in Australia—trends in provision. J Clin Sleep Med. 2007;3:281–4.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Flemons WW, Douglas NJ, Kuna ST, Rodenstein DO, Wheatle J. Access to diagnosis and treatment of patients with suspected sleep apnea. Am J Respir Crit Care Med. 2004;169:668–72. doi: 10.1164/rccm.200308-1124PP.CrossRefPubMedGoogle Scholar
  14. 14.
    Baraitser P, Pearce V, Holmes J, Horne N, Boynton PM. Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health Care. 2007;16:303–7. doi: 10.1136/qshc.2006.020883.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hersberger KE, Renggli VP, Nirkko AC, Mathis J, Schwegler K, Bloch KE. Screening for sleep disorders in community pharmacies—evaluation of a campaign in Switzerland. J Clin Pharm Ther. 2006;31:35–41. doi: 10.1111/j.1365-2710.2006.00698.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Krass I, Mitchell B, Clarke P, Brillant M, Dienaar R, Hughes J, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract. 2007;75:339–47. doi: 10.1016/j.diabres.2006.06.022.CrossRefPubMedGoogle Scholar
  17. 17.
    Mangum SA, Kraenow KR, Narducci WA. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc. 2003;43:50–5. doi: 10.1331/10865800360467042.CrossRefGoogle Scholar
  18. 18.
    Black J, Saini B, Wong K. The role of pharmacists in improving the management of sleep disorders in the Australian Community. Respirology. 2007;12:A24.Google Scholar
  19. 19.
    Johns MW. A new method for measuring daytime sleepiness: the epworth sleepiness scale. Sleep. 1991;14:540–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Maslin G, Pack AI, Kribbs NB, Smith Pl, Schwartz AR, Kline LR, et al. A survey screen for prediction of apnea. Sleep. 1995;18:158–66.CrossRefGoogle Scholar
  21. 21.
    Morin CM. Insomnia: psychological assessment and management. New York: The Guilford Press; 1993. ISBN 1572301201.Google Scholar
  22. 22.
    Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–32. doi: 10.1016/S1389-9457(02)00258-7.CrossRefPubMedGoogle Scholar
  23. 23.
    Jefferson CD, Drake CL, Scofield HM, Myers E, McClure T, Roehrs T, et al. Sleep hygiene practices in a population-based sample of insomniacs. Sleep. 2005;28:611–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Ohayon MM, Lemoine P, Arnaud-Briant V, Dreyfus M. Prevalence and consequences of sleep disorders in a shift worker population. J Psychosom Res. 2002;53:577–83. doi: 10.1016/S0022-3999(02)00438-5.CrossRefPubMedGoogle Scholar
  25. 25.
    Wetter DW, Young TB. The relation between cigarette smoking and sleep disturbances. Prev Med. 1994;23:328–34. doi: 10.1006/pmed.1994.1046.CrossRefPubMedGoogle Scholar
  26. 26.
    Schweitzer PK. Drugs that disturb sleep and wakefulness. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005. ISBN 9780721607979.Google Scholar
  27. 27.
    Bartlett DJ, Marshall NS, Williams A, Grunstein RR. Sleep health New South Wales: chronic sleep restriction and daytime sleepiness. Intern Med J. 2008;38:24–31.PubMedGoogle Scholar
  28. 28.
    Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230–5. doi: 10.1056/NEJM199304293281704.CrossRefPubMedGoogle Scholar
  29. 29.
    Högl B, Kiechl S, Willeit J, Saletu M, Frauscher B. Seppi restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology. 2005;64:1920–4. doi: 10.1212/01.WNL.0000163996.64461.A3.CrossRefPubMedGoogle Scholar
  30. 30.
    Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med. 2007;3:33–6.PubMedGoogle Scholar
  31. 31.
    Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev. 2007;11:35–46. doi: 10.1016/j.smrv.2006.03.006.CrossRefPubMedGoogle Scholar
  32. 32.
    Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes. Am J Respir Crit Care Med. 2005;172:1590–5. doi: 10.1164/rccm.200504-637OC.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA. 2004;291:2013–6. doi: 10.1001/jama.291.16.2013.CrossRefPubMedGoogle Scholar
  34. 34.
    Australian Institute of Health and Welfare. Australia’s health 2008. Canberra: AIHW; 2008. http://www.aihw.gov.au/publications/index.cfm/title/10585 Accessed 20 Nov 2008.
  35. 35.
    Yee B, Campbell A, Beasley R, Neill A. Sleep disorders: a potential role in New Zealand motor vehicle accidents. Intern Med J. 2002;32:297–304. doi: 10.1046/j.1445-5994.2002.00229.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Rosenthal LD, Dolan D. The Epworth Sleepiness Scale in the identification of obstructive sleep apnea. J Nerv Ment Dis. 2008;196(5):429–31.CrossRefPubMedGoogle Scholar
  37. 37.
    Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307.CrossRefPubMedGoogle Scholar
  38. 38.
    Savard M, Savard J, Simard S, Ivers H. Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology. 2005;14(6):429–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Gurubhagavatula I, Maislin G, Nkwuo JE, Pack AI. Occupational screening for obstructive sleep apnea in commercial drivers. Am J Respir Crit Care Med. 2004;170(4):371–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Abetz L, Arbuckle R, Allen R, Garcia-Borreguero D, Hening W, Walters A, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 2006;7(4):340–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless Legs Syndrome prevalence and impact: REST General Population Study. Arch Intern Med. 2005;165(11):1286–92.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Adam Tran
    • 1
  • Joanne M. Fuller
    • 1
  • Keith K. Wong
    • 2
    • 3
  • Ines Krass
    • 1
  • Ron Grunstein
    • 2
    • 3
    • 4
  • Bandana Saini
    • 1
    Email author
  1. 1.Faculty of PharmacyThe University of SydneySydneyAustralia
  2. 2.Sleep & Circadian Research Group, Woolcock Institute of Medical ResearchCamperdown, SydneyAustralia
  3. 3.Department of Respiratory & Sleep MedicineRoyal Prince Alfred HospitalCamperdown, SydneyAustralia
  4. 4.Faculty of MedicineUniversity of SydneySydneyAustralia

Personalised recommendations